Codexis has been granted a patent for acyltransferases that aid in the synthesis of important statin compounds. The patent includes an engineered variant LovD polypeptide with enhanced catalytic activity compared to the wild-type Aspergillus terreus acyltransferase. GlobalData’s report on Codexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Codexis, Bioethanol production GMOs was a key innovation area identified from patents. Codexis's grant share as of February 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered acyltransferase for synthesizing statin compounds
A recently granted patent (Publication Number: US11926857B2) discloses an engineered variant LovD polypeptide with enhanced catalytic activity compared to the wild-type Aspergillus terreus acyltransferase. The engineered variant LovD polypeptide must have at least two-fold greater catalytic activity and at least 90% sequence identity to the wild-type enzyme. Additionally, the variant may include specific substitutions that correlate with increased catalytic activity, thermal stability, reduced aggregation, and enhanced enzyme stability. Various amino acid substitutions are listed, such as A9V, K26E, R28K, and others, that contribute to the improved characteristics of the engineered variant.
Furthermore, the patent describes a method for producing simvastatin using the engineered variant LovD polypeptide. The method involves contacting a monacolin J substrate with the variant polypeptide in the presence of an a-dimethylbutyryl thioester co-substrate, leading to the conversion of monacolin J to simvastatin. Different variations of the method are outlined, including the use of sodium or ammonium salt forms of monacolin J, the addition of activated charcoal, and the use of agents like ammonium hydroxide for precipitating simvastatin. This innovative method offers a more efficient and potentially cost-effective approach to producing simvastatin, a widely used cholesterol-lowering medication.
To know more about GlobalData’s detailed insights on Codexis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
